Zealandpharma

Zealand Pharma is a Danish biotechnology company headquartered in Copenhagen, Denmark, with additional operations in Boston, Massachusetts. The company is dedicated to the discovery, design, and development of innovative peptide-based medicines for people who need them. With a focus on metabolic diseases, Zealand Pharma is advancing a differentiated clinical pipeline with a strong emphasis on obesity and metabolic health. The company has built a robust platform of peptide expertise and has advanced more than 10 drug candidates through its innovative research. Zealand Pharma is publicly traded on Nasdaq under the ticker symbol ZEAL. The company operates at the forefront of peptide drug development, combining deep scientific expertise with a commitment to creating life-changing therapeutics. Through strategic expansion - including establishing new research units in Cambridge, Massachusetts - Zealand Pharma is strengthening its global R&D capabilities to deliver transformative medicines for people living with metabolic diseases.